US Bancorp DE Has $31,000 Holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

US Bancorp DE lowered its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 88.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 848 shares of the company’s stock after selling 6,520 shares during the quarter. US Bancorp DE’s holdings in Amphastar Pharmaceuticals were worth $31,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Victory Capital Management Inc. raised its position in shares of Amphastar Pharmaceuticals by 10.9% in the 3rd quarter. Victory Capital Management Inc. now owns 218,531 shares of the company’s stock valued at $10,605,000 after buying an additional 21,530 shares in the last quarter. Pacer Advisors Inc. grew its position in Amphastar Pharmaceuticals by 51,977.4% in the fourth quarter. Pacer Advisors Inc. now owns 1,350,368 shares of the company’s stock valued at $50,139,000 after acquiring an additional 1,347,775 shares during the last quarter. Wellington Management Group LLP acquired a new position in Amphastar Pharmaceuticals during the third quarter worth about $957,000. XTX Topco Ltd acquired a new stake in Amphastar Pharmaceuticals in the third quarter valued at approximately $674,000. Finally, Geode Capital Management LLC grew its stake in shares of Amphastar Pharmaceuticals by 1.5% during the third quarter. Geode Capital Management LLC now owns 920,363 shares of the company’s stock worth $44,674,000 after buying an additional 14,015 shares during the last quarter. Institutional investors own 65.09% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have commented on AMPH shares. Piper Sandler downgraded Amphastar Pharmaceuticals from an “overweight” rating to a “neutral” rating and dropped their target price for the company from $66.00 to $36.00 in a research report on Tuesday, February 4th. Wells Fargo & Company assumed coverage on Amphastar Pharmaceuticals in a research note on Friday, November 22nd. They issued an “equal weight” rating and a $55.00 price objective on the stock.

Insider Activity at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 4,231 shares of Amphastar Pharmaceuticals stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $27.54, for a total value of $116,521.74. Following the completion of the sale, the chief financial officer now directly owns 97,363 shares of the company’s stock, valued at approximately $2,681,377.02. The trade was a 4.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 27.10% of the stock is owned by corporate insiders.

Amphastar Pharmaceuticals Trading Down 1.2 %

AMPH opened at $27.36 on Wednesday. The company has a fifty day moving average of $32.42 and a 200-day moving average of $40.89. Amphastar Pharmaceuticals, Inc. has a twelve month low of $25.89 and a twelve month high of $53.96. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82. The stock has a market cap of $1.30 billion, a PE ratio of 9.12, a price-to-earnings-growth ratio of 2.19 and a beta of 0.77.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.